<DOC>
	<DOCNO>NCT00610194</DOCNO>
	<brief_summary>Primary Objective : To evaluate safety escalate oral dos RDEA119 , MEK inhibitor , advanced cancer patient . Secondary Objectives : - To describe initial PK different dos RDEA119 give orally Day 1 study - To describe PK different dos RDEA119 give orally continuous dose . - To examine inhibition MEK product ( p-ERK ) , cytokine product , protein biomarkers - To expand MTD dose cohort evaluate safety , tolerability PK/PD recommend Phase 2 dose - To explore presence genotype , PD marker , cell growth marker apoptosis , pair tumor biopsy sample patient ' tumor pre-dose dose minimum 10 patient expand cohort</brief_summary>
	<brief_title>Phase 1 Dose-escalation PK/PD Trial Advanced Cancer Patients</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<criteria>Histological cytological confirm solid tumor . Advanced metastatic locally recurrent disease proven effective therapy exists . In expanded MTD cohort , minimum 10 patient must accessible tumor amendable biopsy ( cut needle ) start study . For patient biopsy group , block patient 's original diagnostic biopsy/excision , available , may use genotype analysis . ECOG performance status 01 . Life expectancy &gt; equal 3 month . Acceptable hematology , clinical chemistry , coagulation laboratory value . Patient must acceptable treatment follow accord Investigator . Patent must agree sign Informed Consent . Patient within normal range cardiac function measure echocardiogram MUGA scan . Use investigational agent device within last 28 day . Major surgery within 30 day start study . Patients document CNS metastasis steroid CNS therapy Evidence uncontrolled active infection . Other serious medical psychiatric illness . Significant cardiac dysfunction include congestive heart failure ( NYHA Class III IV ) ; myocardial infarction ventricular tachyarrhythmia within last 6 month ; major conduction abnormality unless correct cardiac pacemaker ; prolong QTc &gt; 460msec . Patients know hypersensitivity drug component give protocol . Pregnancy . Women men childbearing potential willing use effective contraception , include barrier protection . Patients abdominal fistula , GI perforation , intraabdominal abscess , small bowel resection , within 6 month study entry . Patients abdominal radiation result chronic diarrhea . Because RDEA119 primarily metabolize CYP3A4 CYP2C19 , inhibitor inducer enzymes avoid . Patients know HIV infection exclude .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2014</verification_date>
</DOC>